In the last years, the application of "nanotechnology “to the field of “medicine” surely represented the most innovative strategy to cope with diseases and it could be named as nanomedicine applied to difficult-to-treat diseases. As known, in this field of research, the most important goal to be reached is an increase in selectivity and specificity of drug action. Several results with stimulating findings in preclinical or clinical phases have been reached by using nanocarriers, delivering agents to targeted pathologies, and among them, it is known that neuro-pathologies represent a stimulating issue. In fact, the pharmaceutical treatment of Central Nervous System (CNS) disorders is the second largest area of therapy, following cardiovascular diseases. Nowadays, non-invasive drug delivery systems for CNS are actively studied. In fact, the development of new delivery systems (nanoparticles and liposomes) started with the discovery that properly surface-engineered colloidal vectors, with a diameter around 200 nm, were shown to be able to cross the Blood-Brain Barrier without apparent damage, and to deliver drugs or genetic materials into the brain. During this talk, an overview will be presented considering the most recent literature results of nanomedicine applied to brain diseases, carried out with all the most popular kinds of nanoparticulate systems, focusing in particular on immune-nanoparticles and peptide-decorated nanosystems able to target the CNS, with in vivo and in vitro evidences investigating the pathway for BBB crossing and CNS localization of engineered nanoparticles. The brain localization and the multi-modal pathways for BBB crossing highlighted the endocytosis as preferential pathway; moveover, in vitro test on hippocampal neurons showed the presence of cell-to-cell transport of nanoparticles.References:•A.M. Grabrucker, C. C. Garner, T.M. Boeckers, L. Bondioli, B. Ruozi, F.Forni, M.A. Vandelli, G.Tosi , Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. PLOS ONE, 2011, Vol 6, e17851. •G. Tosi, R.A. Fano, L. Badiali, R. Benassi, F. Rivasi, B. Ruozi, F. Forni, M.A., Vandelli. Investigation on the mechanisms for Blood-Brain Barrier crossing of brain-targeted glycopeptides nanoparticles, Nanomedicine UK, 2011, 6(3), 423-436.•G. Tosi, AV Vergoni, B. Ruozi, L. Bondioli, L. Badiali, F. Rivasi, L. Costantino, F. Forni, M.A. Vandelli, Sialic-acid and glycopeptides conjugated PLGA nanoparticles for Central Nervous System targeting: in vivo pharmacological evidence and biodistribution, Journal of Controlled Release, 2010,145, 49–57.
Nanotechnology in medicine: therapeutic strategies in neurological disorders / Tosi, Giovanni; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Forni, Flavio. - STAMPA. - (2012), pp. 1-1. ((Intervento presentato al convegno Workshop on Nanomedicine and Nanobiosystems tenutosi a Lecce nel 6-8 Settembre 2012.
|Data di pubblicazione:||2012|
|Titolo:||Nanotechnology in medicine: therapeutic strategies in neurological disorders|
|Autore/i:||Tosi, Giovanni; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Forni, Flavio|
|Nome del convegno:||Workshop on Nanomedicine and Nanobiosystems|
|Luogo del convegno:||Lecce|
|Data del convegno:||6-8 Settembre 2012|
|Citazione:||Nanotechnology in medicine: therapeutic strategies in neurological disorders / Tosi, Giovanni; Ruozi, Barbara; Belletti, Daniela; Vandelli, Maria Angela; Forni, Flavio. - STAMPA. - (2012), pp. 1-1. ((Intervento presentato al convegno Workshop on Nanomedicine and Nanobiosystems tenutosi a Lecce nel 6-8 Settembre 2012.|
|Tipologia||Relazione in Atti di Convegno|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris